Aclaris Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
For the full year, the company reported revenue was USD 31.25 million compared to USD 29.75 million a year ago. Net loss was USD 88.48 million compared to USD 86.91 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 1.33 a year ago. Diluted loss per share from continuing operations was USD 1.27 compared to USD 1.33 a year ago.